pembrolizumab
merck
['pembro']
in a phase ii clinical trial of #pembrolizumab, investigators found that 42 percent of patients with metastatic #braincancer benefited from the therapy, with seven patients in the trial surviving longer than 2 years. #asco23. 
Reporting essential clinical news w/ independent analysis for cancer care professionals to optimize patient care & outcomes; oncology/hematology